ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) does about 219.09K shares in volume on a normal day but saw 12867218 shares change hands in the recent trading day. The company now has a market cap of 14.36M USD. Its current market price is $0.58, marking a decrease of -15.09% compared to the previous close of $0.68. The 52 week high reached by this stock is $2.60 whilst the lowest price level in 52 weeks is $0.46.
ImmunoPrecise Antibodies Ltd (IPA) has a 20-day trading average at $0.5773 and the current price is -77.85% off the 52-week high compared with 24.98% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.6553 and its 200-day simple moving average is $1.1476. If we look at the stock’s price movements over the week, volatility stands at 15.53%, which decreases to 12.24% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 47.16 to suggest the stock is neutral.
The consensus objective for the share price is $6.00, suggesting that the stock has a potential upside of 90.33% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 02, 2022 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $9.
The current price level is -0.26%, -12.14%, and -49.83% away from its SMA20, SMA50, and SMA200 respectively, with the IPA price moving above the 50-day SMA on current market day. ImmunoPrecise Antibodies Ltd (IPA) stock is up 7.59% over the week and -11.07% over the past month. Its price is -66.33% year-to-date and -64.89% over the past year.
The stock last released its quarterly earnings report for quarter ended 7/31/2024, with the company’s earnings per share (EPS) of -0.07 above consensus estimates by 0.03. The company’s next earnings report forecasts estimating quarterly EPS at -0.07 and -0.33 for whole year. Expected sales for next quarter are $4.83M, which analysts say will come at $18.22M for the current fiscal year and next year at $24.72M. In addition, estimates put the company’s current quarterly revenue at an average of $4.63M.
To reach the target analysts have set, the stock logically needs to grow 90.33 percent from here.
Outstanding shares total 26.94M with insiders holding 12.73% of the shares and institutional holders owning 6.07% of the company’s common stock. The company has a return on investment of -62.73% and return on equity of -62.82%. The beta has a value of 0.24. Price to book ratio is 0.66 and price to sales ratio is 0.81.
